Starch, Potato

Phase 2Small molecule

UUniversity of Michigan Rogel Cancer Center

Starch, Potato is one of 3 small molecule programs targeting Musculoskeletal. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MusculoskeletalNot yet recruiting

MusculoskeletalPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Musculoskeletal

#DrugCompanyPhaseTrials

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 2

Ferinject

VVifor Pharma

Phase 3

1 3

Starch, Potato

UUniversity of Michigan Rogel Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Musculoskeletal

NCT07443943

Clinical

Trials by Indication[1]

Musculoskeletal1 trial

A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial

Not yet recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT07443943·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Starch, Potato. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Starch, Potato compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Starch, Potato. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Michigan Rogel Cancer Center

Starch, Potato

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Musculoskeletal1 trial

References

Drug Info

Quick Facts

Related News